Spatially resolved osteoblast-traced transcriptomics uncovers TGF-β as a combination target with sclerostin in...

Area of Science:

• Bone biology and regenerative medicine
• Cellular and molecular mechanisms of bone homeostasis

Background:

• Osteoblast dynamics are crucial for bone health but poorly understood due to cellular heterogeneity and lack of spatial context.
• Targeting osteoblast states offers potential for anabolic bone therapies.

Purpose of the Study:

• To investigate the molecular mechanisms regulating osteoblast activation and quiescence.
• To identify novel therapeutic targets for enhancing bone mass and treating osteoporosis.

Main Methods:

• Spatially resolved osteoblast-traced transcriptomics integrating lineage tracing and spatially resolved laser-activated cell sorting (SLACS).
• Single-cell RNA sequencing, in vitro functional assays, and in vivo validation in a mouse model.
• Assessment of dual inhibition of transforming growth factor-beta (TGF-β) and sclerostin.

Main Results:

• Transforming growth factor-beta (TGF-β) signaling identified as a key regulator of osteoblast activation.
• Dual inhibition of TGF-β and sclerostin significantly enhanced bone mass and mitigated bone loss in a hindlimb unloading model.
• Combined therapy proved more effective than sclerostin inhibition alone.

Conclusions:

• TGF-β plays a mechanistic role in regulating osteoblast dynamics and activation.
• A dual-target therapeutic strategy combining TGF-β inhibition with anti-sclerostin treatment shows promise for osteoporosis.
• This study provides insights into osteoblast regulation and potential new avenues for anabolic bone therapy.